Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Contieri

Showing results (91-100 of 138) with videos related to

Pageof 14
Sort By:
BJU International|July 3, 2025
The role of primary tumour site surgery in metastatic UTUC: a systematic review and meta-analysisLudovica Cella, Stefano Moretto, Roberto Contieri, et al.
BMC Cancer|June 4, 2026
Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC)Rosa Tambaro, Gabriele Calvanese, Andrea Muto, et al.
BJUI Compass|October 17, 2024
Impact of Mayo Adhesive Probability score and BMI on renal functional decline after robotic assisted partial nephrectomyCesare Saitta, Marco Paciotti, Giovanni Lughezzani, et al.
European Urology Oncology|February 7, 2026
Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe TrialRoberto Contieri, Marco Paciotti, Alessandro Uleri, et al.
International Urology and Nephrology|February 11, 2025
Key strategies for reducing recurrence in T1 bladder cancer. Evidence from a retrospective multicenter European studyRoberto Contieri, Alexandre Guigui, Bastien Gondran-Tellier, et al.
Future Oncology (London, England)|April 27, 2026
Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancerLudovica Cella, Alessio Finocchiaro, Aleksander Ślusarczyk, et al.
BJU International|January 11, 2025
Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group resultsPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
World Journal of Urology|April 30, 2022
Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomyAmandeep Arora, Ahmed S Zugail, Felipe Pugliesi, et al.
The American Journal of Surgical Pathology|July 1, 2025
International Society of Urological Pathology Consensus Meeting 2024: Working Group 2 Preneoplastic and Precursor Lesions of the Urinary BladderMichelle R Downes, Antonio Lopez-Beltran, Roberto Contieri, et al.
Urologic Oncology|September 20, 2025
The influence of immunocompromised status on recurrence and progression free survival among nonmuscle invasive bladder cancers (NMIBCs) undergoing transurethral resection of bladder tumor (TURBT) and adjuvant intravesical bacillus Calmette Guerin (BCG): Analysis of USA insurance claim dataFrancesco Del Giudice, Valerio Santarelli, Jan Łaszkiewicz, et al.
Pageof 14

Showing results (91-100 of 138) with videos related to

Sort By:
Pageof 14
BJU International|July 3, 2025
The role of primary tumour site surgery in metastatic UTUC: a systematic review and meta-analysisLudovica Cella, Stefano Moretto, Roberto Contieri, et al.
BMC Cancer|June 4, 2026
Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC)Rosa Tambaro, Gabriele Calvanese, Andrea Muto, et al.
BJUI Compass|October 17, 2024
Impact of Mayo Adhesive Probability score and BMI on renal functional decline after robotic assisted partial nephrectomyCesare Saitta, Marco Paciotti, Giovanni Lughezzani, et al.
European Urology Oncology|February 7, 2026
Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non-muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe TrialRoberto Contieri, Marco Paciotti, Alessandro Uleri, et al.
International Urology and Nephrology|February 11, 2025
Key strategies for reducing recurrence in T1 bladder cancer. Evidence from a retrospective multicenter European studyRoberto Contieri, Alexandre Guigui, Bastien Gondran-Tellier, et al.
Future Oncology (London, England)|April 27, 2026
Mitomycin for intravesical treatment of low-grade intermediate-risk non-muscle invasive bladder cancerLudovica Cella, Alessio Finocchiaro, Aleksander Ślusarczyk, et al.
BJU International|January 11, 2025
Gemcitabine and docetaxel for high-risk non-muscle-invasive bladder cancer: EuroGemDoce group resultsPietro Scilipoti, Mattia Longoni, Mario de Angelis, et al.
World Journal of Urology|April 30, 2022
Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomyAmandeep Arora, Ahmed S Zugail, Felipe Pugliesi, et al.
The American Journal of Surgical Pathology|July 1, 2025
International Society of Urological Pathology Consensus Meeting 2024: Working Group 2 Preneoplastic and Precursor Lesions of the Urinary BladderMichelle R Downes, Antonio Lopez-Beltran, Roberto Contieri, et al.
Urologic Oncology|September 20, 2025
The influence of immunocompromised status on recurrence and progression free survival among nonmuscle invasive bladder cancers (NMIBCs) undergoing transurethral resection of bladder tumor (TURBT) and adjuvant intravesical bacillus Calmette Guerin (BCG): Analysis of USA insurance claim dataFrancesco Del Giudice, Valerio Santarelli, Jan Łaszkiewicz, et al.
Pageof 14